IP Library Granted Patent US 11,103,433
Granted Patent B2
US 11,103,433 · App. 15/322,385 · Granted Aug 31, 2021

Antimicrobial-antibiofilm compositions and methods of use thereof for personal care products

Inventors: Purushottam V. Gawande (Winnipeg, CA); Karen Lovetri (Winnipeg, CA); Nandadeva Yakandawala (Winnipeg, CA); Gord Froehlich (Selkirk, CA); Srinivasa Madhyastha (Winnipeg, CA)
Assignee: KANE BIOTECH INC.
A61K8/44A01N37/04A01N37/44A01N59/16A61B3/125A61C11/005A61K8/27A61K8/362A61K8/365A61K9/0048A61K31/194A61K31/198A61K33/30A61K45/06A61Q3/00A61Q17/005A61K2800/70Y02A50/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,103,433
App. No.
15/322,385
Granted
Aug 31, 2021
Kind
B2
Abstract

Compositions comprising one or more chelating agents and optionally zinc ion salts are used to inhibit the growth or biofilm formation in bacteria associated with personal care products such as ophthalmic, pedicure, manicure or podiatric solutions. The compositions of the present application can also comprise gelling agents, antimicrobials, antibiotic or a pH adjuster. The compositions may be in the form of a solution, a gel, a cream, a jelly, a powder, a paste, a lotion, soap and a cleaner.

Claims (21)

1. A composition for inhibiting growth of Methicillin -resistant Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus agalactiae ATCC 12386, Acinetobacter baumannii, Stenotrophomonas maltophilia , Vancomycin-resistant Enterococci, or Proteus mirabilis , or for inhibiting biofilm formation by Methicillin -resistant Staphylococcus aureus, Methicillin -resistant Staphylococcus pseudintermedius, Pseudomonas aeruginosa, Salmonella choleraesuis ATCC 10708, Escherichia coli 0157:H7, Staphylococcus epidermidis , Coagulase-negative Staphylococci, Streptococcus agalactiae ATCC 12386, Klebsiella pneumoniae, Acinetobacter baumannii, Stenotrophomonas maltophilia, Vancomycin -resistant Enterococci, Enterococcus faecalis, Proteus mirabilis , or Malassezia pachydermatis , the composition comprising:

(a) water;

(b) one or more chelating agents selected from the group consisting of disodium or tetrasodium EDTA at a concentration of about 125 to 250 mg/L,

(c) one or more chelating agents selected from the group consisting of sodium citrate, and potassium citrate, at a concentration of about 3,000 mg/L; and optionally

(d) a zinc salt selected from the group consisting of zinc chloride, zinc gluconate, zinc lactate, zinc citrate, zinc sulfate, and zinc acetate.

2. The composition of claim 1 , wherein the zinc salt is zinc chloride or zinc citrate.

3. The composition of claim 1 , wherein the composition comprises:

(i) disodium EDTA and sodium citrate, or

(ii) sodium citrate, disodium EDTA and zinc chloride.

4. The composition of claim 1 , further comprising an antimicrobial preservative selected from one or more of potassium sorbate, potassium benzoate, sodium benzoate and benzoic acid.

5. The composition of claim 1 , further comprising one or more ingredients selected from the group consisting of: water, a buffer, a stabilizing agent, a gelling agent, a surfactant, a herbal, a vitamin, a mineral, an extra cellular matrix, an antimicrobial, an antibiotic, and a pH adjuster.

6. The composition of claim 1 prepared as one or more of a disinfecting solution, a dip solution, a lotion, a cream, an ointment, a gel, and a spray.

7. The composition as claimed in claim 1 , wherein the composition comprises a liposome or nanoparticle or a suitable device delivery system.

8. The composition as claimed in claim 1 , further comprising an anti-infective compound selected from the group consisting of glycoside hydrolase of Aggregatibacter actinomycetemcomitans , alginate lyase, nisin, lactoferricin, serotransferrin, ovotransferrin, ovalbumin, ovomucoid, protamine sulfate, chlorhexidine, cetylpyridinium chloride, triclosan, silver sulfadiazine, benzalkonium chloride, hydrogen peroxide, citric acid, potassium citrate, 5-fluorouracil, cis-2-decenoic acid, DNase I, proteinase K, silver, gallium, silver, bacteriocins and antimicrobial peptides.

9. The composition as claimed in claim 1 further comprising one or more of viscosity enhancing agents, lubricants, surfactants, buffers, preservatives, and salts.

10. The composition as claimed in claim 1 , wherein the composition is selected from a solution, a gel, a cream, a jelly, a powder, a paste, a lotion, a soap and a cleaner.

11. A method of preventing or treating ophthalmic biofilm growth, the method comprising administering the composition of claim 1 to the eye of a user.

12. A method of preventing or treating hand or feet biofilm growth, the method comprising administering the composition of 1 to a foot, fingernail, or toenail of a user.

13. A personal care device treated or impregnated with the composition of claim 1 .

14. The personal care device of claim 13 , comprising one or more of a contact lens and a contact lens container.

15. The personal care device of claim 13 , comprising one or more of a hand washing container, a scrubber, and a foot washing container.

Assignments (3)
SECURITY INTEREST Recorded Nov 9, 2020
From: KANE BIOTECH INC.
To: PIVOT FINANCIAL INC.
Reel/Frame 054307/0264 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 20, 2018
From: MADHYASTHA, SRINIVASA
To: KANE BIOTECH INC.
Reel/Frame 045653/0882 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 9, 2017
From: GAWANDE, PURUSHOTTAM V.; LOVETRI, KAREN; YAKANDAWALA, NANDADEVA; FROEHLICH, GORD
To: KANE BIOTECH INC.
Reel/Frame 041528/0974 →
Cited By (1)
US 12,478,681